BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Celgene International Sárl 

Route de Perreux 1

Boudry    2017  Switzerland
Phone: 41-32-729-85-00 Fax: n/a


SEARCH JOBS




Industry
Pharmaceutical






 Company News
Celgene International Sárl (CELG) Release: Oral OTEZLA® (Apremilast) Data Presented At EADV Show Improved Measures Of Health-Related Quality Of Life And Work Productivity In Patients With Moderate To Severe Plaque Psoriasis 10/10/2014 7:37:02 AM
Celgene International Sárl (CELG) Release: New Analyses Of Oral OTEZLA® (Apremilast) Presented At EADV Show Efficacy In Difficult-To-Treat Areas Of Moderate To Severe Plaque Psoriasis 10/10/2014 7:35:24 AM
Celgene International Sárl (CELG) To Present Long-Term Efficacy And Safety Data On Oral OTEZLA® (Apremilast) In Plaque Psoriasis And Psoriatic Arthritis At European Academy Of Dermatology And Venereology Congress 10/7/2014 8:34:27 AM
Celgene International Sárl (CELG) Release: Results From Phase III Study (AML-001) Of VIDAZA® (Azacitidine For Injection) In Acute Myeloid Leukemia Presented At European Hematology Association 6/16/2014 10:46:25 AM
Celgene International Sárl (CELG) Release: Retrospective Analysis Of Overall Survival Adjusting For Patient Crossover In Phase III Study Of POMALYST®/IMNOVID® (Pomalidomide) In Previously Treated Multiple Myeloma Presented At EHA 6/16/2014 10:44:12 AM
Celgene International Sárl (CELG) Release: First-Of-Its-Kind Multinational Survey Confirms Psoriasis And Psoriatic Arthritis Patients Are Frequently Undertreated Or Not Treated At All 3/20/2014 10:07:58 AM
Celgene International Sárl (CELG) Release: ABRAXANE® Plus Gemcitabine Receives European Marketing Authorization For First-Line Treatment Of Patients With Metastatic Pancreatic Cancer 1/7/2014 8:42:12 AM
Celgene International Sárl (CELG) Release: Studies Evaluating REVLIMID® (Lenalidomide) In Lymphoma Presented At American Society of Hematology 12/11/2013 6:37:04 AM
Celgene International Sárl (CELG) Release: REVLIMID® (Lenalidomide)-Treated Patients With Deletion-5q MDS Who Achieve Transfusion-Independence Of At Least 26 Weeks And AML-Free Survival Associated With Cytogenetic Response 12/10/2013 10:14:07 AM
Celgene International Sárl (CELG) Release: Two Studies Highlight Retrospective Analyses Of Phase III Study Of POMALYST®/IMNOVID® (Pomalidomide) In Previously Treated Multiple Myeloma Patients Presented At American Society of Hematology 12/10/2013 7:17:21 AM
12345678910